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Abstract
Concomitant AAA and abdominal malignancy are always very complicated conditions 
requiring early management of both pathologies. This is undoubtedly a dilemma for a 
surgeon who cannot currently rely on any large randomized trials or mandatory guide-
lines. When making decisions, a surgeon most often relies on personal experience, the 
experience of his/her center and/or limited literary guidelines and recommendations. 
Efforts should be aimed at achieving a consensual multidisciplinary decision about 
which pathology requires “more acute” management. The decision-making process is 
easier if one of the pathologies is life-threatening, and such pathology should be man-
aged first. In most cases, however, AAA is asymptomatic and a malignancy is found 
randomly, as a secondary finding during the follow-up of AAA patients, or vice versa, 
AAA is found randomly during the staging of cancer patients. In these cases, the thera-
peutic algorithm already admits several possible variants. Endovascular repair of AAA 
(EVAR) resulted in an absolute change in the management of these patients. EVAR can be 
used in simultaneous or stage procedures with minimal time delay. Also, surgical open 
resection is an option (simultaneously or staged). It is necessary to know the advantages 
and risks of all approaches.
Keywords: abdominal aortic aneurysm, malignancy, single stage surgery, endovascular 
surgery, simultaneous treatment
1. Introduction
The incidence of abdominal aortic aneurysm (AAA) has been increasing steadily over the last 
40 years [1], and according to recent literature data, it ranges from 15 to 37 cases per 100,000 
population per year, while the prevalence is about 5% in men above 65 years of age [2, 3]. 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
Although the incidence of gastrointestinal or genitourinary tract tumors differs in different 
parts of the world, these are some of the most common intra-abdominal malignancies.
It is therefore logical that AAA can from time to time be diagnosed concurrently with solid 
tumors in the abdominal cavity. The incidence of AAA and concurrent malignancy in the 
abdominal cavity is about 3–13% [4–6]. Some risk factors are common in the etiopathogenesis 
of both AAA and colorectal carcinoma or urinary tract carcinoma. Some papers even report 
a higher occurrence of malignant diseases in AAA patients than in patients presenting with 
atherosclerosis only [7].
One of the first papers to deal with the concomitant AAA and malignant tumor was pub-
lished by Szilagy in 1967 [8]. Its prevalence of patients with synchronous AAA and malignant 
tumors was 3.9%. Of course, tremendous developments have taken place in the treatment 
of both AAA and malignancies over the 50 years that have elapsed since this publication. 
During this time, a number of authors have been involved in this issue. However, they 
have most frequently published case reports or “single center experience” articles describ-
ing a limited population of patients, while multicenter studies have been reported rarely 
[9]. Kouvelos is one of the few authors who has tried to present a larger group of patients in 
his meta-analysis [10]. However, we still lack a large randomized study, and the question is 
whether such study is feasible at all in this field. The reason is the huge heterogeneity of this 
population. Although clear indications criteria for AAA treatment are now widely accepted 
worldwide (asymptomatic over 50–55 mm, symptomatic and rupture of course), regional 
differences are still present in the treatment method (open repair/endovascular approach). 
This inconsistent ‘policy’ is evident both among the various countries of the world and 
among the various institutions in one country. If the AAA does not meet indication criteria 
for AAA therapy, tumor should be treated and AAA is not the issue for treatment at that 
time.
As mentioned above, significant changes have occurred in the surgical and endovascu-
lar treatment options since the days of Szilagy, yet the basic dilemma remains the same. 
Which treatment algorithm to choose? Which pathology to treat earlier? The aneurysm or 
the tumor? Another option is a synchronous procedure (single-stage surgery). Even after 
50 years, the answer to this question cannot be clearly answered. Nevertheless, some recom-
mendations and guidelines can be defined more clearly thanks to the development of endo-
vascular treatment for AAA (EVAR). However, the decision about the treatment strategy for 
a particular patient is not always clear. The logical answer that “a more acute lesion should 
be treated first” may not be sufficient in certain situations. The question is whether we are 
always able to define which pathological finding (AAA or tumor) is more acute. A number 
of factors may play a role in this decision. Concerning the aneurysm, these are mainly the 
size, the risk of rupture, anatomy, localization, and symptoms. Concerning the tumor, such 
factors may include the type, localization, biological nature (grading), extent (staging), and 
the overall condition of the patient. Other factors may play a role, such as the potential need 
for further neoadjuvant or adjuvant oncological treatment (chemotherapy, radiotherapy) 
and, last but not least, the decision of the surgeon can be influenced by the patient’s opinion, 
who may express some wishes that must be respected despite being a nonprofessional in 
this field.
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Two basic extreme situations are usually beyond discussion: an AAA rupture always requires 
urgent management, be it a resection or endovascular treatment. Due to the urgency of the 
situation and the complexity of the procedure, we do not attempt to manage any tumor in the 
vast majority of cases. Tumor management comes later, after the convalescence of the patient. 
In rare cases, where AAA rupture has been managed without any circulatory problems and 
without major blood loss, an intra-abdominal tumor can be managed at the same time, pro-
vided that such procedure is relatively simple and uncomplicated. An ill-considered effort 
to manage everything at one time often leads to failure. An analogous situation may occur 
in confirmed generalized malignancy, which we are unable to influence by therapy, and the 
patient has a very limited life-expectation, thus we do not indicate any procedure even in 
large AAA. If rupture occurs, we can try to perform an acute procedure, but even this remains 
an ethical question. In the case of terminal phase of malignancy is ethical to refuse the sur-
gery. Fortunately, these two extreme situations do not present in the vast majority of cases in 
patients with concomitant AAA and abdominal cavity tumor. More frequently, the patient is 
diagnosed with AAA during CT scanning for intra-abdominal tumor staging, or vice versa, a 
patient followed-up for AAA can be diagnosed with a malignancy during regular check-ups.
Then the crucial decision comes… “what first? … or simultaneously?” It is necessary to know 
the advantages and risks of the respective approaches. With the “tumor first” approach, the 
patient gets the benefit of early elimination of the malignancy with a lower risk of local pro-
gression and distant spreading, but at the cost of a certain risk of rupture in the postoperative 
period. An increased risk of AAA rupture after laparotomy has been repeatedly published in 
the literature, whether due to changes in the abdominal cavity, local irritation of AAA, but 
also due to collagenolysis caused by postoperative stress and nutritional depletion [11–13]. 
Subsequent chemotherapy may also have an effect on AAA [14], according to some authors. 
When choosing the “AAA first” approach, we delay the removal of the malignant tumor with 
its potential consequences. In this situation, however, it is absolutely crucial what type of 
AAA treatment we choose. Mini-invasive EVAR, which is preferred in this case, will mini-
mally delay the tumor resection, the convalescence is very short, usually several days, and the 
subsequent procedure can be performed very soon. However, we are not always in a position 
to choose EVAR, either due to the AAA anatomy (angulation and neck length, tortuosity or 
calcification of the iliac arteries), or purely for logistical reasons, such as the inability to obtain 
the required stent-graft in time (in particular for juxtarenal or pararenal AAAs). In these cases, 
we choose a resection method of treatment, which certainly leads to a significant delay in 
tumor treatment. Similarly, operational stress and the subsequent catabolic phase can lead 
to progression of the malignancy. Finally, in the selected group of patients, a third option, 
single-stage surgery, can be chosen, and EVAR or AAA resection is performed together with 
tumor resection. The main risk is the possibility of graft infection, which differs in different 
types of tumor (colorectal/kidney/liver).
As mentioned above, the development of endovascular repair has played a major role in 
choosing a strategy for the treatment of concomitant tumors of the abdominal cavity and 
AAA in recent decades. Multiple debates have been going on around the world about the 
benefits and disadvantages of open repair versus EVAR. A number of studies have been con-
ducted, usually with expected conclusions in the short-term follow-up but already slightly 
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controversial within the long-term: EVAR 1, EVAR 2, DREAM, OVER [15–18]. However, the 
presented results are “aging” very quickly given the continuing development of stent-grafts, 
with their latest generations promising, in particular, better long-term results. Yet, in the 
short-term, EVAR, of course, reduces perioperative morbidity, reduces the need for blood 
transfusions, and reduces hospitalization. Similarly, there has been good development in the 
surgical treatment of abdominal cavity tumors. More and more procedures can be minimally 
invasive using laparoscopy or robotics, thereby reducing perioperative stress and burden for 
the patient, especially when choosing a synchronous procedure or the “tumor first” strategy 
[19, 20].
If the EVAR approach was chosen, we have to consider with later postoperative follow-up. 
CT angiography is still gold standard but less invasive procedures as a contrast ultrasound or 
even regular ultrasound are often sufficient. Periodically CTA examinations can also serve as 
a dispenzarisation after malignancy resection.
Knowing the above information, we can now discuss the individual types of malignancy 
and outline the treatment options. The authors present their own experience obtained at a 
university clinic, which is a high-volume center for both AAA treatment and the treatment 
of a complete range of malignancies. Their experiences are confronted with literary data. The 
presented recommendations can be seen as personal experience, supplemented by guidelines 
generally accepted in the scientific literature.
We need perfect diagnostic backgrounds to make a precise and rational decision regarding 
treatment strategy. Knowledge of the size and anatomy of AAA, the local extent of the tumor, 
its resectability, and staging are the key information we need to know before any surgical 
procedure.
2. Diagnosis
Ultrasound is often the first tool to reveal the diagnosis of intra-abdominal malignancies and 
AAA. This can include screening tests in completely asymptomatic patients or primary imaging 
used to evaluate the patient’s symptoms. Later, however, it is always supplemented by more 
precise techniques to better assess the specific situation. As part of the diagnosis of abdomi-
nal aortic involvement, computer tomography (CT angiography, CTA) is the method of first 
choice, which precisely determines the extent of aneurysmal dilation, maximum dimension of 
the aneurysm, character of the aortic wall, involvement of the visceral branches, presence of 
thrombus, etc. CT scanning is able to reveal with high sensitivity and specificity an aneurys-
mal rupture which may sometimes be “covered” in the first stage and does not form a typical 
hematoma in the retroperitoneum. Certainly, there have been efforts to identify “high-risk” 
aneurysms that are at high risk of rapid progression and rupture. To date, only absolute dimen-
sion and rate of AAA progression have been demonstrated to be significant factors. Continued 
efforts have been made to find a marker on CTA which would indicate an imminent risk of 
rupture. A number of research facilities have participated in the development of software 
that works with biomechanical analysis and AAA modeling to evaluate the pressure on the 
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aneurysm wall, high-risk sites, the role of intraluminal thrombus, etc. [21–24]. Commercially 
available software is now available that aims to predict rupture based on information obtained 
from CTA. However, the research in this field is still to a certain extent experimental, and no 
extensive studies have been conducted to confirm the benefits of this method for common diag-
nosis in clinical practice. In a slightly different way, research is underway to predict rupture 
based on ECG-triggered CT angiography, a condition where software evaluates AAA behavior 
during pulse-wave analysis. A number of studies are already available in this field, confirm-
ing that analysis of aortic wall distensibility can reveal a high-risk AAA [25, 26]. Despite all 
this research, it is not yet possible to reliably distinguish a stable aneurysm, which remains 
unchanged or undergoes minimal progression only over a long period of time, from aneu-
rysms at high risk of rupture even despite having a smaller dimension. CTA is often used as the 
premier method for the diagnosis of tumors of the liver (requiring multiphase examination), 
and kidneys, and often also for evaluating the staging of all malignant tumors in the abdominal 
cavity, including stomach or colorectal tumors (Figure 1).
Digital subtraction angiography (DSA) is only minimally used in the diagnosis of AAA, and 
can be used in cancer surgery for the visualization and occlusion of vessels nourishing the 
malignant tumor within a specific preoperative preparation.
Magnetic resonance imaging (MRI) may be added, especially in liver tumors, but also in 
tumors of the retroperitoneum or soft tissue tumors. MRI combined with contrast-enhanced 
ultrasound (CEUS) or with CT safely differentiates malignant liver tumors from benign 
lesions (focal nodular hyperplasia, hemangioma, and adenoma). In this way, we can obtain 
key information to decide whether the tumor management can be postponed or acute treat-
ment is needed.
Figure 1. AAA and rectosigmoid tumor (CTA).
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In recent years, hybrid methods have also been added to the diagnostic portfolio, such as pos-
itron emission tomography and CT (PET CT), positron emission magnetic resonance imaging 
(PET MRI). These methods, which are commonly used for the diagnosis of malignancies, or 
their staging or follow-up, may also sufficiently reveal the presence of any pathology on the 
abdominal aorta, including AAA (Figures 2–5). In some cases, it may also raise the suspicion 
of an inflammatory etiology of AAA, and its increased risk [27, 28]. These methods are able to 
reveal the extent of the malignancy with high sensitivity.
Endoscopic examination, whether esophagogastroscopy or colonoscopy, is always included 
in the diagnosis of stomach, duodenal and colorectal tumors. Occasional concerns of gastro-
enterologists about the use of these endoscopic techniques in patients with a large AAA are 
not based on any valid literary data. Classical colonoscopy can sometimes be replaced with 
virtual CT colonography [29].
Figure 2. Multiple metastases of colorectal carcinoma in the liver and aortic dissection (PET CT).
Figure 3. AAA (PET MRI).
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3. Gastrointestinal tract tumors
3.1. Tumors of the stomach
The most common tumor is stomach carcinoma, which is more common in men, with a 
maximum occurrence in the 6th and 7th decades of life. The only curative treatment is radical 
tumor resection, and total gastrectomy is indicated if the tumor is in the stomach body. Other 
supportive forms of treatment, such as chemotherapy or actinotherapy, have been reported 
to fail, because it is a very aggressive tumor in biological terms. If generalization is present, 
no resection therapy is indicated in most cases, and therefore no procedures are indicated on 
the aortic aneurysm, either. The patient’s life expectancy in these cases is several months. If a 
resectable nongeneralized gastric carcinoma occurs concomitantly with AAA (about 2–3.8%) 
[30], early aggressive radical therapy is advisable (Figure 6). In the event of a symptomatic 
AAA or AAA at risk of rupture, it is best to indicate EVAR treatment, which can soon be 
Figure 5. AAA and osteolytic metastasis in the vertebral body (PET CT).
Figure 4. Metastases of colorectal carcinoma in the liver (PET MRI).
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followed by resection of the tumor. However, EVAR in the first stage of treatment followed 
by early cancer surgery can also be indicated for asymptomatic AAA. We should not delay 
the procedure on the stomach due to the biological nature of the disease, and the time interval 
between the individual procedures may be several days. Stomach surgery is absolutely indi-
cated in the first stage in the case of tumor hemorrhage or perforation. Similarly, we believe 
it is advisable to indicate the stomach procedure first followed by early EVAR in AAA, which 
is stable and shows no risk of rupture according to the surgeon. A synchronous procedure is 
also theoretically possible, especially when both findings are symptomatic or require acute 
management. If the endovascular procedure is not contraindicated, we always prefer this 
solution as part of the synchronous procedure. AAA resection and gastrectomy as single-
stage surgery is a very extensive procedure and would often be over-limit for the patient. 
The risk of graft infection is minimal in the synchronous procedure [31–33]. If EVAR cannot 
be performed for some reason, and we have to choose two-stage surgery, it is possible to use 
retroperitoneal access for AAA resection (either in the first or second stage). In this way, we 
can avoid penetration into the peritoneal cavity and prevent later preparation in scar tissues 
during the second procedure. Similarly, a laparoscopic resection of the stomach can be chosen 
within the mini-invasive approach [34–35].
Recommendation: in the most common situation, where both pathologies are asymptomatic 
in terms of risk of AAA rupture or gastric bleeding, we choose malignant tumor surgery in the 
Figure 6. AAA and stomach tumor (CTA).
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first stage and subsequently early endovascular AAA treatment. Even the reverse order of the 
two-stage procedure is possible, with the stomach procedure being delayed by several days.
3.2. Colorectal tumors
Colorectal carcinomas are among the most common tumors worldwide, and many European 
countries rank high in regard to their occurrence. They are relatively slow growing tumors, 
but their metastatic spread often does not correlate with tumor size. Treatment consists of 
tumor resection and potential subsequent adjuvant chemotherapy. Certain exceptions are 
locally advanced rectal carcinoma, where preoperative neoadjuvant radiotherapy is indicated. 
In colorectal tumors concomitant with AAA (about 0.5–3.9%) [30], the symptomatic pathol-
ogy should be treated first again, e.g., a tumor causing bowel obstruction (Figure 7) or bleed-
ing vs. symptomatic painful aneurysm at high risk of rupture. In most cases, however, both 
lesions are asymptomatic and we have to decide about the treatment strategy. Being aware 
of the higher risk of AAA rupture after previous laparotomy and of the biological nature of 
colorectal carcinoma, a two-stage approach should be considered, with EVAR being indicated 
early after resection of the colorectal carcinoma [11, 36]. For these types of tumors, delaying 
the intestinal procedure by several days brings minimal risk of malignancy progression. This 
approach is also beneficial in terms of possible early initiation of adjuvant chemotherapy fol-
lowing tumor resection. Similarly, in rectal tumor, especially if it is locally advanced and 
infiltrates the surrounding structures, neoadjuvant radiotherapy is primarily indicated before 
surgery. This may be complicated in the future before subsequent aneurysm surgery, whether 
using the open-repair or EVAR approach. Therefore, we believe it is again more advisable to 
indicate EVAR first and to treat the tumor subsequently.
This procedure can also be combined into a single-stage treatment, where EVAR is immedi-
ately followed by a surgical procedure on the intestine, where the risk of stent-graft infection 
Figure 7. AAA and stenotic colon cancer (CTA).
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is reported to be minimal even when handling the large intestine (about 0.5%) [33]. In fact, this 
number is basically lower than the general risk of aortic replacement infection in open AAA 
surgery. Recently, the mini-invasive approach, i.e., laparoscopic procedures on the colon and 
rectum, has been increasingly used in colorectal surgery. This may extend the portfolio of our 
procedures in some way, especially if AAA cannot be managed by endovascular repair. If we 
decide to start with the intestinal procedure, it is more than convenient to use the laparoscopic 
or robotic approach.
With our current capabilities, we are able to use the laparoscopic approach for virtually any 
procedure in the area of intestinal surgery. Today, laparoscopic procedures are considered to 
be a standard and noninferior compared to open surgery procedures, and continuous efforts 
have been made to improve the technique and procedures to further extend the indications 
and possibilities of this mini-invasive approach. Laparoscopic surgery procedures are now 
also indicated in patients in whom they were previously contraindicated. The most common 
cause of these contraindications was previous surgery in the abdominal cavity, obesity, or 
severe comorbidities, including the presence of AAA. There are no clear literature evidence 
for higher risk of AAA rupture during laparoscopy. Despite the fact that the laparoscopic 
approach can be used to perform any procedure in colorectal surgery, the percentage of lapa-
roscopic procedures is still lower than that of open surgery procedures, and is about 20% in 
the area of colorectal surgery. This percentage applies primarily to clinical facilities. Literary 
data clearly confirm that laparoscopic procedures reduce hospitalization time, the length of 
incapacity to work and return to normal life, and in our case, improve the possibility of further 
surgical procedures on the aorta [37, 38]. The biggest advantage is the mini-invasive approach 
itself, less trauma of the abdominal wall, less postoperative pain, less analgesics and early 
rehabilitation and mobilization. Concerning obesity, this is no longer an absolute contraindi-
cation to the laparoscopic approach; patients with a body mass index (BMI) of more than 35 
are commonly operated on. Obesity markedly impairs the ease of surgery, but the procedure 
is usually technically feasible. The benefits of laparoscopy for this group of patients is quite 
high also for another reason: these patients are often at risk of laparotomy dehiscence during 
open surgery, which then leads to further surgical procedures and potentially increases the 
risk of a possible AAA rupture. This is also associated with a lower percentage of general 
complications in the surgical wound area. The issue of radicality, the number of lymph nodes 
in the resection and survival of patients is comparable to open surgery [39].
From our point of view, a laparoscopic or robotic approach is very beneficial in situations 
where we are planning an additional surgical procedure on the aorta after intestinal surgery. 
One of the most important factors is that gentle mini-invasive surgery results in minimal 
perioperative stress and minimal postoperative changes.
Figure 8 shows a minilaparotomy after laparoscopic resection of the upper rectum for car-
cinoma, in which EVAR was subsequently indicated for increasing AAA. Such a finding 
certainly cannot be categorized as a “hostile abdomen” and further potential access to the 
abdominal cavity is uncomplicated.
Recommendations: for the concomitant occurrence of asymptomatic AAA (which how-
ever meets the indication criteria for treatment) and tumor in the colorectal area, we most 
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frequently choose a staged surgery approach, where we prefer EVAR in the first stage and 
subsequently the intestinal procedure (open or laparoscopic). The reverse order is also pos-
sible. In a two-stage surgical approach, we prefer to choose retroperitoneal access to the aorta. 
A one-stage approach can be chosen in a selected patient group, but this is always associated 
with a risk of aortic graft infection. We try to avoid this risk by specific measures (AAA resec-
tion first, colon resection is started after careful closure of the retroperitoneum, protected 
vascular graft (antibiotic, silver), antibiotic prophylaxis).
4. Tumors of the liver and biliary tract
The most common primary liver tumors are primary hepatocellular carcinoma (HCC) or chol-
angiocellular carcinoma (CCC). However, secondary tumors (up to 90%) are predominant in 
Europe, including metastasis of colorectal carcinoma, carcinoma of the stomach, pancreas, 
kidneys, mammary glands, etc. Primary liver tumors, as well as gallbladder or biliary tract 
carcinomas, are biologically very aggressive, with early generalization. Radical resection is 
the only curative treatment at their early stage without generalization, and other therapeutic 
methods are only palliative in nature. The incidence of concomitant AAA and primary hepa-
tocellular carcinoma is about 0.3–0.8% [30]. Even here, it is necessary to consider whether 
any of the pathological findings is immediately associated with a risk of acute complications. 
Figure 8. Status postlaparoscopic resection of the rectum.
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If symptomatic or extensive AAA with a potentially high risk of rupture is not present, it is 
preferable to first choose surgical treatment of an aggressive malignancy and subsequently 
continue with an early endovascular procedure on AAA. An example of this procedure is 
shown in Figures 8 and 9, which shows a coincidence of a doubtfully resectable Klatskin 
tumor and asymptomatic AAA. Here, it is certainly advisable to indicate immediate treat-
ment of the malignancy in the first stage. Of course, the reverse order is also possible, starting 
with EVAR followed by early tumor surgery. But in this case, we should consider the risk of 
later stent-graft malposition during the procedure in the abdominal cavity. A slightly differ-
ent view is available in the case of secondary metastasis in the liver parenchyma (Figure 10). 
If the disease is treatable (e.g., solitary metastasis or a limited number of colorectal carcinoma 
metastases) and can be managed by liver resection, we first try to perform endovascular AAA 
repair and continue with an early surgical procedure on the liver. Hepatic metastases of other 
carcinomas (stomach, gallbladder, and pancreas) unfortunately mostly indicate a very poor 
prognosis of the disease and no radical procedure is indicated. Even synchronous treatment, 
including EVAR with hepatic resection, is generally not excluded in liver tumors. If we cannot 
use EVAR, then the two-stage procedure is the method of choice, and again retroperitoneal 
(Rutherford) access to the aorta can be used to prevent subsequent postoperative changes in 
the abdominal cavity.
Figure 9. Klatskin tumor and AAA (PET CT).
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In the vast majority of cases, we try to avoid synchronous open AAA resection and extensive 
resection of the liver, which would be associated with a disproportionate risk of high blood 
loss, and a possible risk of infection of the aortic graft. Of course, synchronous treatment can 
be chosen where small peripheral tumors are present that can be removed by minor resection. 
More than ever, however, we must take care of precise hemostasis in the resection area (using 
sutures on the clamp, thermal ablation techniques, harmonic scalpel, and so on). Cell-saver 
can be helpful in these cases.
Mini-invasive ablation techniques for liver tumor destruction (cryoablation and radiofre-
quency ablation) can also be added to open AAA resection.
Recommendation: in primary malignant liver tumors (HCC, CCC), we prefer to choose 
tumor resection in the first stage of treatment, followed by early EVAR. If there is no unnec-
essary delay, EVAR can be indicated in the first stage of treatment even in this case, and 
cancer surgery can be added subsequently. In liver metastasis of colorectal carcinoma, we 
may also allow a moderate delay in the liver procedure (often while undergoing adjuvant 
chemotherapy), and therefore, it is possible to first indicate EVAR, or less frequently an open 
aortic procedure. We should avoid simultaneous resection of AAA and larger resection of the 
liver parenchyma due to the disproportionate risk associated with this procedure.
Figure 10. AAA and liver metastasis (PET MRI).
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5. Tumors of the kidney
The most common kidney tumors originate from the renal parenchyma, and less commonly 
from the pelvis. Renal cell carcinoma affects men twice as often as women. Its maximum 
occurrence is between 45 and 75 years of age. The only curative method of treatment is radical 
tumor resection or nephrectomy (depending on tumor size). These tumors are rather aggres-
sive in terms of biological behavior, with early establishment of distant metastatic lesions. 
The incidence of their concomitant occurrence with AAA is about 1.3–2% [30]. Again, we 
should consider which pathology is more acute. EVAR can be followed by a renal procedure 
virtually immediately in several days (laparoscopic management is preferred today), includ-
ing nephrectomy. Of course, the reverse order of the two-stage procedure is possible as well, 
with the initial procedure on the kidney followed by early EVAR surgery. The second variant 
is also supported by the existence of a potential, albeit low, risk of stent-graft malposition 
during the subsequent nephrectomy. Given the close anatomical location of AAA and the kid-
ney, a simultaneous open procedure is more commonly indicated in these cases. A resection 
procedure on the kidney, including nephrectomy, is relatively straightforward but does cause 
additional burden for the patient compared to simple AAA resection. Especially in the case 
of a left kidney tumor, we choose an optimal retroperitoneal approach, which is an optimal 
approach to both the renal parenchyma and the aorta. For malignancies on the right side, we 
must choose a transperitoneal approach. A typical case suitable for simultaneous open access 
is shown on Figure 11, where the endovascular procedure would include a fenestrated or 
branched stent-graft implantation, and the subsequent renal procedure would be associated 
Figure 11. Juxtarenal AAA and renal cell carcinoma (CTA).
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with the above risks. A simultaneous open procedure in this case will optimally manage both 
pathologies in a single-stage procedure. These procedures are not even associated with a 
higher risk of graft infection. Advanced kidney tumors (T3, T4) with intracaval thrombus 
are a specific situation, where surgical treatment is also indicated in selected patients, and 
any aortic manipulation would cause a risk of fatal thrombus embolism in the pulmonary 
vasculature; in this case, we prefer initial nephrectomy with cavotomy and removal of the 
tumor thrombus, followed by subsequent AAA management (by an early EVAR procedure, 
if possible).
Recommendations: again, a two-stage procedure can be chosen to manage the simultaneous 
occurrence of AAA and kidney tumor, and the EVAR procedure should be preferred again, 
irrespective of the order. It is more advisable to initiate with tumor management, followed by 
a subsequent EVAR procedure, whether in terms of early malignancy management or stent-
graft malposition. However, a simultaneous open procedure; i.e., AAA resection and kidney 
tumor resection, including nephrectomy, is indicated more frequently in this area.
6. Other tumors
Cases of concomitant AAA and pancreatic tumors are less common, and similar rules apply as 
for primary tumors of the liver, gallbladder and biliary tract. Due to the tremendous aggres-
siveness of the tumor, the pancreatic procedure is always indicated first (unless acute AAA-
related symptoms are present), while an EVAR procedure is indicated in the second stage. In 
patients with an inoperable malignant pancreatic tumor, no aortic procedure is indicated in 
the vast majority of cases. Coincidence of AAA that cannot be managed by an endovascular 
procedure for any reason and pancreatic tumor is a difficult situation. Here, we must pro-
ceed strictly on an individual basis and consider the optimal approach. However, an open 
AAA resection with hemipancreatoduodenectomy is not possible, because this simultaneous 
procedure would be associated with a disproportionate risk of perioperative and postopera-
tive complications. We therefore prefer a two-stage procedure, where it is undoubtedly more 
appropriate to use the retroperitoneal access to the aorta (whether it is the first or the second 
stage).
In retroperitoneal tumors, no procedure can generally be recommended, and multiple factors 
should be considered, such as size and type, location, and in particular biological behavior of 
the tumor. For malignant tumors, we should prefer extirpation as early as possible, while in 
uncomplicated procedures, we can use simultaneous AAA resection. However, a two-stage 
procedure is also available for the latter, with EVAR being preferable to open surgery.
Prostate tumors are often managed by minimally invasive surgery (laparoscopic or robotic 
prostatectomy, transurethral procedures). So, prostate surgery in the first stage will have 
minimal effects on the AAA or on the access to potential AAA resection. More often, however, 
we choose an endovascular procedure, which can be performed simultaneously in indicated 
cases. A similar approach is chosen for bladder tumors.




Our university facility includes both a center of vascular surgery with a high number of 
patients treated for AAA, and a cancer center addressing a complete spectrum of all cancer 
diseases. For these reasons, we repeatedly encounter patients who have been diagnosed with 
concomitant AAA and a solid tumor in any location. Of course, the presence of a tumor in 
the abdominal cavity is a specific situation. If a tumor occurs concomitantly with AAA in any 
location other than the abdominal cavity, the decision about the treatment strategy is much 
easier. In the absence of an acute indication for AAA management, surgical treatment for 
the malignancy is preferable at our facility in the vast majority of cases, which is followed by 
early AAA management (surgical or endovascular). A different situation occurs when AAA 
is present concomitantly with an intra-abdominal cancer. We are aware that any treatment for 
one pathology directly affects the other, and therefore this situation always poses a dilemma 
for us, as described above, and is carefully considered in a multidisciplinary team. We always 
try to manage each case on an individual basis, but we still follow certain literary guidelines 
and use our personal experience.
Over the period from 2000 to 2016, we operated on 1097 patients with AAA, of which 37 
patients had a concomitant malignant tumor in the abdominal cavity (3.4%). See Table 1.
For each patient, we always used an individual approach, considering the AAA size, symp-
toms and the risk of rupture, as well as the tumor type, its location, biological nature, and risk 
of progression of malignancy. The general condition of the patient was also considered. We 
tried to find the optimal solution in the given situation, but we also respected the patient’s 
own opinion. All discussions take place in a multidisciplinary team (vascular surgeon, 
radiointerventional radiologist, oncologist, and internist). Our experiences are presented in 
Table 2.
The mean length of hospitalization was 14.9 (±7.1) days for a simultaneous procedure, and 
12.3 (±9.3) days for a multistage procedure. The difference was not statistically significant.
The morbidity rate was 24.2% for the simultaneous procedure, and 20.1% for the multistage 
procedure. Again, the difference was not statistically significant.
No vascular graft infection or stent-graft infection was recorded in any patient, either in the 
simultaneous or multistage group.
The mortality rate was 11.5% for simultaneous procedures, and 6.9% for multistage proce-





Table 1. Intra-abdominal tumors diagnosed concomitantly with AAA.
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8. Summary
Concomitant AAA and abdominal malignancy is always a very complicated condition requir-
ing early management of both pathologies. This is undoubtedly a dilemma for a surgeon who 
cannot currently rely on any large randomized trials or mandatory guidelines.
Endovascular repair of AAA (EVAR) resulted in an absolute change in the management of these 
patients. EVAR can be used in simultaneous or multistage procedures (in any order) with mini-
mal time delay. EVAR is also associated with a minimal risk of stent-graft infections, even in 
simultaneous procedures. For these reasons, we clearly prefer EVAR in these cancer patients, 
unless clear contraindications are present. Some authors also address the financial issues of the 
respective options; the authors of this paper believe that in these specific and relatively rare cases, 
treatment costs should not play a role in decision-making regarding the treatment strategy.
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